New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" - https://www.reportlinker.com/p06021776/?utm_source=GNW
The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.
The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period: CMOs Offering Vector Manufacturing Services for Cell and Gene Therapy Companies Robust Cell & Gene Therapies in the Pipeline Increase in Strategic Acquisitions Regulatory Support for Cell and Gene Therapy Products
The study considers the present scenario of the Europe cell and gene therapy market and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Europe Cell and Gene Therapy Market Segmentation The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.
Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.
Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patients quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.
Product Cell Therapies Gene Therapies End-user Hospitals Cancer Care Centers Wound Care Centers Others Application Oncology Dermatology Musculoskeletal Others
INSIGHTS BY GEOGRAPHY Germany, France, the UK, Italy, and Spain play a significant role in the Europe cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. In addition, the target patient population is increasing across Europe; there were an estimated 3.9 million new cases of cancer and 1.9 million cancer deaths in Europe in 2018. In addition, the prevalence surveys in the UK and Denmark indicate that there are 34 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes that are involved in the development of cell and gene therapies are expected to boosting the market in Europe.
Geography Europe o UK o Germany o France o Italy o Spain o Switzerland o Netherlands
INSIGHTS BY VENDORS Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors. While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.
Prominent Vendors Novartis Spark Therapeutics Amgen Gilead Sciences Organogenesis
Other Prominent Vendors APAC Biotech AVITA Medical bluebird bio CHIESI Farmaceutici CollPlant CO.DON Human Stem Cells Institute PJSC (HSCI) Medipost NuVasive Nipro Orchard Therapeutics RMS Regenerative Medical System Orthocell Osiris Therapeutics Sibino GeneTech Shanghai Sunway Biotech Takeda Pharmaceutical Company Terumo Vericel
Emerging Investigational Vendors In Europe Adaptimmune Therapeutics AgenTus Therapeutics Autolus Cellecits Celyad CombiGene EUKARS Freeline Therapeutics Innoskel PsiOxus Therapeutics Ltd SparingVision uniQure
KEY QUESTIONS ANSWERED 1. What is the Europe cell and gene therapy market size and growth rate during the forecast period? 2. What are the factors driving the demand for CAR-T therapy in the European region? 3. How are strategic acquisitions aiding in market growth of cell and gene therapy products? 4. Which segments are expected to generate the highest revenues during the forecast period? 5. Who are the leading vendors in the European cell and gene therapy market?Read the full report: https://www.reportlinker.com/p06021776/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Originally posted here:
- Difference Between Ex Vivo and In Vivo Gene Therapy - December 30th, 2022 [December 30th, 2022]
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - December 30th, 2022 [December 30th, 2022]
- Gene therapy | Description, Uses, Examples, & Safety Issues - December 30th, 2022 [December 30th, 2022]
- Cell and gene therapy: Biopharma portfolio strategy | McKinsey - December 30th, 2022 [December 30th, 2022]
- History of Gene Therapy | Discovery and Evolution - December 30th, 2022 [December 30th, 2022]
- What is Gene Therapy? | FDA - U.S. Food and Drug Administration - December 30th, 2022 [December 30th, 2022]
- Gene Therapy Gel Offers New Hope Against Rare Blistering Disease - December 30th, 2022 [December 30th, 2022]
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - December 6th, 2022 [December 6th, 2022]
- New Treatments for Retinitis Pigmentosa - American Academy of ... - December 6th, 2022 [December 6th, 2022]
- The Era of One-Shot, Multimillion-Dollar Genetic Cures Is Here - WIRED - December 6th, 2022 [December 6th, 2022]
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022 [November 4th, 2022]
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022 [November 4th, 2022]
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022 [November 4th, 2022]
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022 [November 4th, 2022]
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022 [November 4th, 2022]
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022 [November 4th, 2022]
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022 [November 4th, 2022]
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022 [November 4th, 2022]
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022 [November 4th, 2022]
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022 [November 4th, 2022]
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022 [November 4th, 2022]
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022 [November 4th, 2022]
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022 [November 4th, 2022]
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022 [November 4th, 2022]
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022 [November 4th, 2022]
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022 [November 4th, 2022]
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022 [November 4th, 2022]
- Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Gene therapy can make a real impact on global health but we need equitable access, say experts - World Economic Forum - October 19th, 2022 [October 19th, 2022]
- Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022 - Managed Healthcare Executive - October 19th, 2022 [October 19th, 2022]
- Carmine Gets Series A Funding to Develop Non-viral Gene Therapy |... - Cystic Fibrosis News Today - October 19th, 2022 [October 19th, 2022]
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 19th, 2022 [October 19th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 19th, 2022 [October 19th, 2022]
- Survey Reveals Most People with Spinal Muscular Atrophy Using New Gene Therapies, Focused on Treatment Pipeline - PR Newswire - October 19th, 2022 [October 19th, 2022]
- GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma - October 19th, 2022 [October 19th, 2022]
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 19th, 2022 [October 19th, 2022]
- Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss(1) - Canada NewsWire - October 19th, 2022 [October 19th, 2022]
- A sound approach for effective gene therapy delivery to brain - The Source - Washington University in St. Louis - Washington University in St. Louis - October 19th, 2022 [October 19th, 2022]
- Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of... - October 19th, 2022 [October 19th, 2022]
- LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission - BioSpace - October 19th, 2022 [October 19th, 2022]
- Health News Roundup: Serum Institute to produce Ebola vaccine for use in Uganda outbreak; Eli Lilly to buy gene therapy company Akouos for $487... - October 19th, 2022 [October 19th, 2022]
- New Pittsburgh biomanufacturing center to accelerate cell and gene therapy innovation - BioPharma-Reporter.com - August 30th, 2022 [August 30th, 2022]
- Trinity team's new gene therapy shows promise for treating eye condition affecting millions across the globe - Ophthalmology Times - August 30th, 2022 [August 30th, 2022]
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022 [August 30th, 2022]
- Defining the Impact of Gene Therapy - Managed Healthcare Executive - August 30th, 2022 [August 30th, 2022]
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022 [August 30th, 2022]
- India Gene Therapy Market Research Report 2022: Prospects, Trends, Market Size and Forecasts to 2028 - ResearchAndMarkets.com - Business Wire - August 30th, 2022 [August 30th, 2022]
- Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022 [August 30th, 2022]
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022 [August 30th, 2022]
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Gene therapies for lung cancer identified by international team of scientists - Labiotech.eu - August 30th, 2022 [August 30th, 2022]
- BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace - August 30th, 2022 [August 30th, 2022]
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - Yahoo Finance - August 30th, 2022 [August 30th, 2022]
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022 [August 30th, 2022]
- What is the difference between sickle cells and healthy RBCs? - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials - HDBuzz - August 30th, 2022 [August 30th, 2022]
- Cell therapy weekly: Kyverna Therapeutics appoints new Senior Vice President - RegMedNet - August 30th, 2022 [August 30th, 2022]
- GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy - BioSpace - August 30th, 2022 [August 30th, 2022]
- Document: Big Pharma exec: COVID shots are 'gene therapy' - July 8th, 2022 [July 8th, 2022]
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - July 8th, 2022 [July 8th, 2022]
- Gene therapy - Mayo Clinic - July 8th, 2022 [July 8th, 2022]
- FDA approves novel gene therapy to treat patients with a rare form of ... - July 8th, 2022 [July 8th, 2022]
- Adeno-Associated Virus (AAV) as a Vector for Gene Therapy - July 8th, 2022 [July 8th, 2022]
- Gene therapy: Where the action is for retinal diseases - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Adverum cuts jobs, restructures to give eye gene therapy another shot - BioPharma Dive - July 8th, 2022 [July 8th, 2022]
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS - Labiotech.eu - July 8th, 2022 [July 8th, 2022]
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Business Wire - July 8th, 2022 [July 8th, 2022]
- TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" - PR Newswire - July 8th, 2022 [July 8th, 2022]
- AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Gene Therapy Market is Expected to Grow Revenue up to USD 20 Billion by 2028 Know More with Infinium Global Research - Digital Journal - July 8th, 2022 [July 8th, 2022]
- Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week - The Motley Fool - July 8th, 2022 [July 8th, 2022]
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022 [July 8th, 2022]
- Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World - July 8th, 2022 [July 8th, 2022]
- Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy -... - July 8th, 2022 [July 8th, 2022]
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021 [December 27th, 2021]
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021 [December 27th, 2021]